RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia
Conditions
Warm Autoimmune Hemolytic Anemia
Trial Timeline
Aug 11, 2020 → Apr 1, 2021
NCT ID
NCT04253236About RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly is a phase 2 stage product being developed by Immunovant for Warm Autoimmune Hemolytic Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04253236. Target conditions include Warm Autoimmune Hemolytic Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04253236 | Phase 2 | Terminated |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |